Economics of end-of-life care in the intensive care unit

End-of life care is in need of improvement, yet little is known about the effectiveness or cost of various end-of-life therapies. Economic analyses are used to help make decisions between two or more therapies when resources are constrained. In this chapter, we review the various types of economic analyses, the costs of dying, and how healthcare reform has impacted these costs. Finally, we discuss the unique issues associated with cost-effectiveness studies of palliative therapy, with emphasis on the problem of calculating a cost-effectiveness ratio when there is no good measurement for valuing the quality of death. It is likely that methods for conducting a cost-effectiveness analyses for end-of-life care will need to evolve or alternative strategies such as cost-benefit analysis or distributive justice will be needed to inform resource allocation decisions. As the national debate about healthcare costs, access, and quality continues, we will increasingly turn to economic analyses to help make resource allocation decisions. Cost-effectiveness analysis will continue to be the most popular form of economic analysis because it combines the results (effectiveness of treatment) with the costs of achieving the results. We must be aware of the limitations of cost-effectiveness analyses and the need for value judgments when using cost-effectiveness analyses to inform healthcare decisions.

[1]  J. Lynn,et al.  Quality improvements in end of life care: insights from two collaboratives. , 2000, The Joint Commission journal on quality improvement.

[2]  P. Pronovost,et al.  Organizational characteristics of intensive care units related to outcomes of abdominal aortic surgery. , 1999, JAMA.

[3]  P. Singer,et al.  Quality end-of-life care: patients' perspectives. , 1999, JAMA.

[4]  B. Rapkin,et al.  End-of-life decision-making in the hospital: current practice and future prospects. , 1999, Journal of pain and symptom management.

[5]  L. Stepp.  Approaching Death: Improving Care at the End of Life , 1998, Annals of Internal Medicine.

[6]  E. Emanuel,et al.  The promise of a good death , 1998, The Lancet.

[7]  E S Fisher,et al.  Variation in carotid endarterectomy mortality in the Medicare population: trial hospitals, volume, and patient characteristics. , 1998, JAMA.

[8]  P. Eggers,et al.  Potentially ineffective care in intensive care. , 1998, JAMA.

[9]  J. Lynn,et al.  Capitated Risk‐Bearing Managed Care Systems Could Improve End‐of‐Life Care , 1998, Journal of the American Geriatrics Society.

[10]  B. Rooney,et al.  Death and end-of-life planning in one midwestern community. , 1998, Archives of internal medicine.

[11]  L. Lenert,et al.  Method of Medicare reimbursement and the rate of potentially ineffective care of critically ill patients. , 1997, JAMA.

[12]  G. Rubenfeld,et al.  Aggressive Medical Care at the End of Life: Does Capitated Reimbursement Encourage the Right Care for the Wrong Reason? , 1997 .

[13]  Roger B. Davis,et al.  Outcomes and Cost-effectiveness of Initiating Dialysis and Continuing Aggressive Care in Seriously Ill Hospitalized Adults , 1997, Annals of Internal Medicine.

[14]  W. Suki,et al.  The Ad Hoc Committee report on estimating the future workforce and training requirements for nephrology. The Ad Hoc Committee on Nephrology Manpower Needs. , 1997, Journal of the American Society of Nephrology : JASN.

[15]  W. Knaus,et al.  The Illusion of End‐of‐Life Resource Savings with Advance Directives , 1997, Journal of the American Geriatrics Society.

[16]  J. Lynn,et al.  Measuring Quality of Care at the End of Life: A Statement of Principles , 1997, Journal of the American Geriatrics Society.

[17]  D. Angus,et al.  Risk prediction: judging the judges , 1997, Intensive Care Medicine.

[18]  D. Wagner,et al.  Prognoses of seriously ill hospitalized patients on the days before death: implications for patient care and public policy. , 1997, New horizons.

[19]  J. Luce,et al.  Increasing incidence of withholding and withdrawal of life support from the critically ill. , 1997, American journal of respiratory and critical care medicine.

[20]  M C Weinstein,et al.  The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. , 1996, JAMA.

[21]  D. Angus,et al.  Cardiopulmonary resuscitation: what cost to cheat death? , 1996, Critical care medicine.

[22]  Milton C. Weinstein,et al.  Recommendations for Reporting Cost-effectiveness Analyses , 1996 .

[23]  M. Weinstein,et al.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine. , 1996, JAMA.

[24]  J. Lave,et al.  The effect of managed care on ICU length of stay: implications for medicare. , 1996, JAMA.

[25]  L. Watkins,et al.  The Nearly Good, the Bad, and the Ugly in Cost-Effectiveness Analysis of Health Care , 1996 .

[26]  M. Drummond,et al.  Economic Analysis Alongside Clinical Trials: Bias in the Assessment of Economic Outcomes , 1996, International Journal of Technology Assessment in Health Care.

[27]  Jonathan J Deeks,et al.  META‐ANALYSIS, DECISION ANALYSIS AND COST‐EFFECTIVENESS ANALYSIS: METHODS FOR QUANTITATIVE SYNTHESIS IN MEDICINE. , 1996 .

[28]  E. Emanuel.  Cost savings at the end of life. What do the data show? , 1996, JAMA.

[29]  James R. Allen,et al.  Good Care of the Dying Patient , 1996 .

[30]  Good care of the dying patient. Council on Scientific Affairs, American Medical Association. , 1996, JAMA.

[31]  D. Angus,et al.  The influence of clinical study design on cost-effectiveness projections for the treatment of gram-negative sepsis with human anti-endotoxin antibody. , 1995, Journal of critical care.

[32]  William A. Knaus,et al.  A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT). The SUPPORT Principal Investigators. , 1995, JAMA.

[33]  L. Esserman,et al.  Potentially ineffective care. A new outcome to assess the limits of critical care. , 1995, JAMA.

[34]  Erry,et al.  Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. , 1995, The New England journal of medicine.

[35]  D. Asch,et al.  Decisions to limit or continue life-sustaining treatment by critical care physicians in the United States: conflicts between physicians' practices and patients' wishes. , 1995, American journal of respiratory and critical care medicine.

[36]  L. Goldman,et al.  The SUPPORT Prognostic Model: Objective Estimates of Survival for Seriously Ill Hospitalized Adults , 1995, Annals of Internal Medicine.

[37]  J. A. Kruse,et al.  A Proposed Model for the Cost of Cardiopulmonary Resuscitation , 1994, Medical care.

[38]  K C Cain,et al.  Measuring Preferences for Health States Worse than Death , 1994, Medical decision making : an international journal of the Society for Medical Decision Making.

[39]  J. Mahoney.  Cost savings at the end of life. , 1994, The New England journal of medicine.

[40]  J. Lubitz,et al.  Trends in Medicare payments in the last year of life. , 1993, The New England journal of medicine.

[41]  J. Studnicki,et al.  Intensive care, survival, and expense of treating critically ill cancer patients. , 1993, JAMA.

[42]  J. Iglehart.  The American health care system. Medicare. , 1992, The New England journal of medicine.

[43]  H. Glick,et al.  Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis. Economic assessment of a new therapeutic agent. , 1991, JAMA.

[44]  A. Detsky,et al.  A clinician's guide to cost-effectiveness analysis. , 1990, Annals of internal medicine.

[45]  D. Feeny,et al.  Utilities and Quality-Adjusted Life Years , 1989, International Journal of Technology Assessment in Health Care.

[46]  R M Kaplan,et al.  A general health policy model: update and applications. , 1988, Health services research.

[47]  H. Brachinger,et al.  Decision analysis , 1997 .

[48]  A. Fasoli.  [Clinical decision analysis]. , 1986, Annali italiani di medicina interna : organo ufficiale della Societa italiana di medicina interna.